Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + Pertuzumab in Neoadjuvant HER2+ Breast Cancer
NCT07393425Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Feb 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07393425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393425.